We develop global regulatory strategies for oncology, immuno-oncology, hematologic malignancies, rare diseases, biologics, viral vectors, bispecific antibodies, plasma-derived therapies, controlled substances, and small molecules. We align clinical, CMC, nonclinical, safety, quality, and manufacturing functions around a unified roadmap, conducting early gap assessments to mitigate risks from early-stage planning through lifecycle management.

We prepare, author, and lead complete, compliant, and agency-ready submissions including INDs, CTAs, NDAs, sNDAs, BLAs, DMFs, and briefing books. We expertly guide innovative modalities and emerging technologies through expedited INDs, orphan drug designations, rare pediatric disease strategies, pediatric study plans, and global accelerated development pathways.

We lead critical interactions with global agencies, including the FDA (CDER, CBER, CDRH), EMA, and Health Canada, by preparing teams, developing briefing packages, and managing written responses. Simultaneously, we oversee eCTD execution using Extedo, GlobalSubmit, and Freyr, while strengthening templates, SOPs, and inspection-readiness processes.

We provide hands-on regulatory leadership tailored specifically to the unique needs of small or virtual biotechs. We provide senior-level leadership without the cost of a full-time executive, stepping in precisely where you need us most, whether as an interim regulatory lead, a project-based strategist, or an ongoing advisor.